
Intellia Therapeutics NTLA
€ 10.83
1.0%
Quartalsbericht 2025-Q3
hinzugefügt 06.11.2025
Intellia Therapeutics Langfristiger Schuldenstrom 2011-2026 | NTLA
Langfristiger Schuldenstrom Jährlich Intellia Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.2 M | 18.6 M | 16.7 M | 9.11 M | 5.7 M | 5.74 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 20.2 M | 5.7 M | 12.7 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Adagene
ADAG
|
1.18 M | $ 1.9 | -3.11 % | $ 107 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.31 | -4.06 % | $ 7.96 B | ||
|
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
6.8 M | $ 25.87 | -0.79 % | $ 1.25 B | ||
|
Aptose Biosciences
APTO
|
428 K | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Athira Pharma
ATHA
|
414 K | - | - | $ 269 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 215.29 | 4.59 % | $ 5 B | ||
|
BioNTech SE
BNTX
|
39.5 M | $ 105.97 | -2.78 % | $ 27.2 B | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.71 | 1.88 % | $ 17 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
7.29 M | $ 64.74 | 1.41 % | $ 8.66 B | ||
|
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.96 | -1.0 % | $ 8.62 B | ||
|
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | ||
|
BioLineRx Ltd.
BLRX
|
522 K | $ 2.97 | 3.12 % | $ 908 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Biogen
BIIB
|
86.4 M | $ 164.87 | 0.27 % | $ 24 B | ||
|
Bio-Path Holdings
BPTH
|
103 K | - | - | $ 100 K | ||
|
BioVie
BIVI
|
74.5 K | $ 1.23 | 2.07 % | $ 1.82 M | ||
|
Baudax Bio
BXRX
|
5.6 M | - | 0.59 % | $ 63 K | ||
|
Calithera Biosciences
CALA
|
1.37 M | - | -10.95 % | $ 876 K | ||
|
Athersys
ATHX
|
1.01 M | - | 3.77 % | $ 22.4 M | ||
|
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M |